T Cell Lymphoma Pipeline Insight
DelveInsight’s, “T-Cell Lymphoma - Pipeline Insight, 2022,” report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in T-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
T-Cell Lymphoma Understanding
T-Cell Lymphoma: Overview
T cell lymphomas (TCL) are a very heterogeneous group of lymphoid malignancies derived from mature T cells differing by localization, pathological features, and clinical presentation. T-Cell Lymphomas can develop in lymphoid tissues such as the lymph nodes and spleen or outside of lymphoid tissues (i.e., gastrointestinal tract, liver, nasal cavity, skin, and others). TCL represents approximately 12% of all non‐Hodgkin lymphomas (NHLs) and is divided into cutaneous TCL (CTCL) and peripheral TCL (PTCL), which themselves are subdivided into nodal or extranodal (systemic) types. Lymphomas that arise from mature T cells are sometimes categorized together under the general term peripheral T-Cell Lymphoma, distinguishing them from the lymphoma that arises from immature T cells or lymphoblastic lymphoma.
"T-Cell Lymphoma - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the T-Cell Lymphoma pipeline landscape is provided which includes the disease overview and T-Cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth T-Cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, T-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence T-Cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve T-Cell Lymphoma.
T-Cell Lymphoma Emerging Drugs Chapters
This segment of the T-Cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T-Cell Lymphoma Emerging Drugs
SP-02: Solasia Pharma
SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organoarsenic) being developed for the treatment of various hematologic and solid cancers. In a US Phase II study, darinaparsin demonstrated clinical activity evidence in lymphoma, particularly PTCL. Furthermore, the Phase I study done in the US and the Pan-Asian Phase 1 study demonstrated positive efficacy and safety of SP-02. The drug is currently being evaluated in Phase III clinical trials to treat patients with Peripheral T Cell Lymphoma. Solasia has begun preparing for the NDA Filing of SP-02.
CC-486 (Azacitidine) is an orally-active form of Vidaza, a chemical analog of the cytosine nucleoside used in DNA and RNA. The main mechanism of action is thought to be hypomethylation of DNA and direct cytotoxicity to abnormal hematopoietic cells in the bone marrow. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. CC-486 is indicated for the treatment of acute myeloid leukemia in first remission. The drug is in Phase III clinical studies for the treatment of T-Cell Lymphoma.
IMC-001: ImmuneOncia Therapeutics
IMC-001 (STI-3031) is a fully human anti-PD-L1 IgG1 type monoclonal antibody that has shown promising results in terms of safety and efficacy in the dose-escalation first-in-human study although the patients were heavily pretreated. IgG1 type antibody targeting PD-L1 on tumor enables unique combinations, such as with an NK cell-based therapy, unique in its property among other PD-1/PD-L1 targeting agents.
Geptanolimab: Genor Biopharma
Geptanolimab (GB226) is an investigational, humanized, anti-PD-1 (IgG4) monoclonal antibody. National Medical Products Administration (NMPA) has accepted and granted priority review to new drug application (NDA) of geptanolimab for relapsed and refractory PTCL. The drug is in clinical studies to treat alveolar soft part sarcoma, cervical cancer, non-Hodgkin’s lymphoma, liver cancer, colorectal cancer, and non-small cell lung cancer. Genor BioPharma has development rights in China for GB226, and Apollomics retains worldwide rights to APL-501 (geptanolimab) outside of China.
Daratumumab: Janssen Research and Development
Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a person’s immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death). Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture, and commercialize daratumumab from Genmab.
Further product details are provided in the report……..
T-Cell Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different T-Cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in T-Cell Lymphoma
There are approx. 85+ key companies which are developing the therapies for T-Cell Lymphoma. The companies which have their T-Cell Lymphoma drug candidates in the most advanced stage, i.e. preregistration include, Genor Biopharma.
DelveInsight’s report covers around 85+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
T-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Bispecific antibody
- CAR-T cell therapies
- Gene therapies
- Cell therapies
- Monoclonal antibodies
- Recombinant proteins
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
T-Cell Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses T-Cell Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T-Cell Lymphoma drugs.
T-Cell Lymphoma Report Insights
- T-Cell Lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
T-Cell Lymphoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing T-Cell Lymphoma drugs?
- How many T-Cell Lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of T-Cell Lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the T-Cell Lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for T-Cell Lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?